Organization
Shulan (Hangzhou) Hospital
4 abstracts
Abstract
First-in-human study of ZGGS18, a dual specific antibody targeting VEGF and TGF-β, as monotherapy in patients with advanced solid tumors.Org: ChangSha TaiHe Hospital, Shulan (Hangzhou) Hospital, Deyang People's Hospital, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Anhui Provincal Hospital,
Abstract
Phase I safety and preliminary efficacy of PM1009, a bispecific antibody targeting TIGIT and PVRIG, in patients with advanced solid tumors.Org: Shanghai East Hospital, Tongji University, Shanghai, China, School of Medicine, Zhejiang University, Hangzhou, China, Tongji University School of Medicine, Shanghai Henlius Biotech, China National Biotec Group,
Abstract
First-in-human study of ZG005, a dual specific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors.Org: Jilin Cancer Hospital, Changchun, China, Department of Medical Thoracic Oncology, Jilin Cancer Hospital, Changchun, China, Shulan (Hangzhou) Hospital, Hangzhou, China,
Abstract
Gilteritinib plus azacitidine and venetoclax for FLT3-ITD mutated relapsed/refractory acute myeloid leukemia.Org: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, First Affiliated Hospital of Wannan Medical College, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China, Shulan (Hangzhou) Hospital, Zhejiang Shuren University Shulan International Medical College,